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Background: Ovarian cancer is the deadliest gynaecologic malignancy. Despite progresses in chemotherapy and
ultra-radical surgeries, this locally metastatic disease presents a high rate of local recurrence advocating for the role
of a peritoneal niche. For several years, it was believed that tumor initiation, progression and metastasis were merely
due to the changes in the neoplastic cell population and the adjacent non-neoplastic tissues were regarded as
bystanders. The importance of the tumor microenvironment and its cellular component emerged from studies on
the histopathological sequence of changes at the interface between putative tumor cells and the surrounding
non-neoplastic tissues during carcinogenesis.
Method: In this review we aimed to describe the pro-tumoral crosstalk between ovarian cancer and mesenchymal
stem cells. A PubMed search was performed for articles published pertaining to mesenchymal stem cells and specific
to ovarian cancer.
Results: Mesenchymal stem cells participate to an elaborate crosstalk through direct and paracrine interaction with
ovarian cancer cells. They play a role at different stages of the disease: survival and peritoneal infiltration at early
stage, proliferation in distant sites, chemoresistance and recurrence at later stage.
Conclusion: The dialogue between ovarian and mesenchymal stem cells induces the constitution of a pro-tumoral
mesencrine niche. Understanding the dynamics of such interaction in a clinical setting might propose new
therapeutic strategies.
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Ovarian cancer is the most lethal gynecologic malig-
nancy in developed countries, responsible for 5.8% of
cancer related deaths [1]. The mainstay of treatment in-
volves cytoreductive surgery associated with platinium
and taxane-based chemotherapy [2]. Despite tremendous
progresses in surgical practice and the broad range of
chemotherapy or targeted therapy available, only low im-
provement has been achieved in survival outcomes these
past 10 years [3-11]. Patients’ clinical course remains un-
predictable, although most of them are optimally treated,
with no residual disease after surgical debulking: 60% of* Correspondence: dox_94@yahoo.fr
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unless otherwise stated.women presenting with advanced-stage at baseline will
recur within 5 years [12,13]. Therefore, 5-year overall
survival remains low (around 45% including all stages)
mainly due to peritoneal recurrences, suggesting the
existence of occult sanctuaries where cancer cells are
protected against treatment. Several authors have deter-
mined tumor autonomous parameters associated with
treatment resistance [14,15]. Moreover, heterogeneity of
ovarian cancers between and within subtypes has been
illustrated by transcriptomic and genetic profiling [16].
Finally copy number variation analysis has revealed sig-
nificant differences between matched primary ovarian
tumor and peritoneal metastases [17]. Beyond these cell
autonomous features, tumor environment may also con-
tribute to the development of clinical relapse.
Tissues are comprised of different cell types that com-
municate to maintain homeostasis [18]. While architecture
of normal tissue is lost in cancer, tumor cells maintainl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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and extra-cellular matrix (ECM) to create a specific tumor
contexture [19]. Both primary and metastatic lesions
get infiltrated by diverse stromal cell types, including
endothelial cells (ECs), immune cells, fibroblasts and bone
marrow-derived cells such as macrophages, mast cells and
mesenchymal stem cells (MSCs) [20]. Stromal cells contrib-
ute to cancer growth and metastasis, through modulation
of different pathways [21-27]. The interactions between
cancer and stromal cells are thus primordial for tumor biol-
ogy as the corresponding crosstalk induces phenotype
changes resulting in stromal “activation” and tumor promo-
tion in both primary and metastatic sites [28,29]. Therefore,
the microenvironment plays a major role in cancer spread,
beyond tumor cell autonomous mechanisms [30] and
might have clinical consequences [31].
Understanding the mechanisms governing the rela-
tionship between cancer and stromal cells is thus essen-
tial to target tumor progression. Among the different
peritoneal cells, MSCs are a cornerstone for cancer
spread through their participation in the establishment
of the pre-metastatic niche and the induction of meta-
static and chemo-resistant phenotypes [21,22,25,32-34].
Here we review the complex role of mesenchymal cells
in ovarian cancer progression and subsequently illustrate
the constitution of a multi-parameter “mesencrine” niche.
Mesenchymal stem cells: a multipotent partner
Although they were initially described in the bone mar-
row [35-38], MSCs may participate to the constitution
of the blood vessel walls and thus be ubiquitous cells,
belonging to virtually all organs [39-41]. As a subset
of pericytes, they can potentially originate from a peri-
vascular niche [42-46]. MSCs are adherent cells that
have a fibroblastic morphology (Figure 1). They are
capable of forming colonies (termed colony-forming
unit fibroblastic) when selected by adhering to plastic
surfaces [38]. Their identification is based on diverse
surface markers, including CD105, CD73, CD90, CD166,
CD44 and CD29.
MSCs play a major role in tissue homeostasis through
the following characteristics: stemness, self-renewal and
multipotence [47]. Their participation in tissue repair
has been suggested by their capacity to differentiate in
different cell types including osteoblasts, adipocytes and
chondrocytes [38,48-50]. However, they usually do not
differentiate into resident cell types of injured tissue as
supported by the therapeutic value of their conditioned
media [51]. Furthermore they exhibit low and transient
engraftment in the damaged organs [52]. Their rep-
arative function may thus operate through paracrine
(“mesencrine”) factors [53].
MSCs also serve as niche cells for other cell types, by
regulating regenerative processes. Indeed, they participateto both hematopoietic cells expansion and hematopoietic
stem cells (HSCs) regulation [54-57]. In particular, they
contribute to self-renewal and differentiation of HSCs
through their regulation of the osteogenic niche [58-61].
MSCs have a primordial role in immune tolerance
[42,62]. Their immunosuppressive effect on T lympho-
cytes and dendritic cells may prevent self-responses in
both physiological and pathological conditions [63,64].
In addition to their regenerative and immunomodulatory
properties, MSCs contribute to tissue healing through
many trophic abilities, such as: (i) inhibition of apoptosis
and fibrosis; (ii) stimulation of angiogenesis; (iii) recruit-
ment and regulation (proliferation and differentiation) of
stem and progenitor cells; (iv) attenuation of oxidative
stress [65]. Therefore, they display a wide range of func-
tions, including cell regeneration, immunomodulation
and stimulation of angiogenesis. Considering their di-
verse abilities, MSCs may thus constitute a key cell in
the neoplastic niche, as supported by their incorporation
into the stroma of solid tumors [66-68] (Figure 2).
MSCs engraftment into tumoral stroma leads to
pro-tumoral crosstalk
Recruitment of cancer-associated MSCs
Bone marrow-derived MSCs are mobilized in blood cir-
culation of patients presenting with advanced-stage ovarian
cancer [34]. Interestingly, they normalize after complete
cyto-reductive surgery. Such observation indicates a poten-
tial role for the interactions between ovarian cancer cells
(OCCs) and MSCs during tumorigenesis.
Indeed, tumors act as unhealed wounds producing
a continuous source of inflammatory mediators [69],
resulting in the recruitment of other cell types, including
MSCs [70-72]. Cancer cells hijack the cytokine machin-
ery to acquire phenotypic advantages in proliferation
[73], angiogenesis [74] and invasive and migratory prop-
erties [75-77]. The cytokine machinery is thus widely
deregulated in advanced ovarian cancer, as supported by
the amplification of many genes encoding cytokines in
OCCs [17,78]. Such deregulation leads to bone marrow-
derived and resident-tissue MSCs engraftment into tumor
stroma through increased release of chemo-attractant
soluble factors [79]. Many cytokines are involved in
their recruitment, including IL-6, SDF1 (stroma derived
factor 1), prostaglandine E2 (PGE2), PDGF and LL-37
(leucine, leucine-37) [21,80].
Educating MSCs to build a permissive tumoral environment
In ovarian cancer, the crosstalk between tumor and stromal
cells leads to bilateral phenotype modulation. Indeed, be-
sides OCCs phenotypic modifications, the phenotype of
cancer-associated MSCs will evolve. Although it may differ
from a cancer type to another, the shift in MSCs phenotype
after their integration into tumor stroma mostly results in
Figure 1 Morphological aspect of Mesenchymal Stem Cells (MSCs) cultivated in vitro. (A) Confocal microscopy showing intercellular
interaction through Tunneling Nanotubes. (B) Optical microscopy illustrating the classical fibroblast-like shape of MSCs (×10).
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cancer cells induce MSCs de novo CCL5 (RANTES) secre-
tion which then acts as a paracrine mediator of increased
motility, invasion and metastatic abilities of the tumor cells
[68]. Once they engraft in ovarian neoplastic microenvir-
onment, cancer-associated MSCs display an expression
profile distinct from bone marrow MSCs, with an in-
creased expression of BMP-2, BMP-4 and BMP-6, and asignificant downregulation of PDGFRβ and TBX5 [81].
This pro-tumoral shift in phenotype is mediated, at least
partially, by tumor-derived secreted factors.
LL-37 enhances MSCs secretion of IL-1β, IL-6, IL-8,
IL-10 and TNFα while diminishing the secretion of
IL-12 [82], with a positive impact on tumor growth.
MSCs exposed to LL-37 stimulate endothelial cell tu-
bule formation in vitro suggesting concomitant increased
Figure 2 Mesenchymal Stem Cells (MSCs) co-cultivated in vitro with Ovarian Cancer Cells (OCCs). (A) Confocal microscopy: eGFP-MSCs
(green) interact with PKH26-OCCs (red). (B) Optical microscopy showing how cancer and mesenchymal cells organize in vitro (×10).
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around endothelial structures and acquire a pericyte-like
differentiation [82]. Lysophosphatidique acid (LPA) is a
small bioactive phospholipid produced by OCCs that stim-
ulates differentiation of MSCs in myofibroblast-like cells
[83-85]. These activated fibroblasts, also termed cancer-
associated fibroblasts (CAFs), are a cornerstone in theestablishment of tumor environment. MSCs incorporation
into tumor stroma is thus associated with a morphological
shift toward CAF-like phenotype, including expression of
myofibroblast-like cell markers (α-SMA, desmin, VEGF),
proteins involved in the regulation of ECM structure
(Tn-C, Tsp-1, SL-1) and tumor promoting factors [22].
The underlying mechanism governing this differentiation
Figure 3 The cytokine-mediated crosstalk between Mesenchymal Stem Cells (MSCs) and Ovarian Cancer Cells (OCCs) leads to a shift in
MSCs phenotype resulting in tumorigenesis promotion. MSCs are recruited to tumor stroma from a peri-vascular niche. Their engraftment is
associated with phenotypic modulations in response to tumor-derived secreted factors. Primed MSCs support tumor growth and self-renewal.
Their differentiation in cancer-associated fibroblasts (CAFs) contributes to stromal modifications suitable for tumor expansion and stimulates
angiogenesis. We highlight the role of HOXA9 expression that results in transcriptional activation of the gene encoding TGFβ2 inducing in turn
CAFs expression VEGF.
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[86]. Interestingly, exosomes from different ovarian cancer
cell lines (OVCAR-3 and SKOV-3) activate different MSCs
signaling pathways (SMAD and AKT, respectively), sug-
gesting that exosome content may vary according to cancer
cell phenotype and thus modulate the tumor stroma differ-
ently. A genomic approach also correlates OCCs ability
to induce CAFs features in MSCs with the expression of
HOXA9, a Mullerian-patterning gene [87]. HOXA9 ex-
pression results in transcriptional activation of the gene
encoding TGFβ2 that induces MSCs expression of IL-6,
VEGF-A and SDF1. Schauer et al. have described a circuit
whereby OCCs secrete IL-1β instructing a CAFs niche
through p53 inhibition [31]. In return, the CAFs niche
secretes IL-8, growth regulated oncogene-alpha (GRO-α),
IL-6 and VEGF. Therefore, the modulation of MSCs
phenotype contributes to generate a cytokine mediated
inflammatory contexture suitable for tumor progression.Once MSCs differentiate into CAFs they participate
in the formation of fibrovascular networks within the
tumor [22,88]. CAFs contribute to the perivascular
matrix through the production of desmin and α-SMA
[22]. CAFs secrete versican, a large ECM proteoglycan
which production is up regulated by TGFβ via TGFβ-RII
and SMAD signaling [89]. Up regulated versican then
promotes OCCs motility. Their expression of the metal-
loprotease MMP-3 also participates in ECM regulation
[22]. The resulting stromal modifications (increased ves-
sel stability and matrix degradation) are compatible with
tumor expansion, stimulated simultaneously by CAFs re-
lease of tumor-supportive growth factors, including HGF,
EGF, IL-6 and SDF1 [88]. Ovarian tumors display in-
creased expression of SDF1 in both CAFs and OCCs.
SDF1 actively participates in the development of tumor
environment and promotes tumor growth through com-
plex mechanisms. First, it reduces local immunity and
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cytoid dendritic cell precursors resulting in poor anti-
tumoral T cell activation through local overexpres-
sion of IL-10 and TNFα [90,91]. SDF1 also induces a
dose-dependent proliferation of OCCs by its specific
interaction with the receptor CXCR4, leading to transac-
tivation of EGFR [92]. It participates as well in adhesion
and trans-endothelial migration of cancer cells through
MAP and Akt kinase regulation [93,94]. SDF1 promotes
angiogenesis at tumor sites: hypoxia synchronously stim-
ulates tumor SDF1 and VEGF production resulting in
synergistic induction of angiogenesis [95]. SDF1 also acts
as a chemo attractant for endothelial progenitor cells
(EPCs) CXCR4 + [96].
Noteworthy, direct intercellular interaction partici-
pates in phenotypic and environmental changes. Indeed,
we have shown in a co-culture setting that MSCs triggered
pro-metastatic properties in OCCs, including adherence,
invasion and migration through the modification of cancer
cells transcriptomic profile [32].
Induction of tumor plasticity: the cancer stem cell (CSC) theory
The CSC theory if clinically confirmed may represent be
an extreme form of cancer cell phenotypic plasticity.
CSCs are defined with the following criteria: (i) self re-
newal, (ii) reproducible tumor phenotype, (iii) restricted
to a minority among entire cell population, (iv) differen-
tiation into non-tumorigenic cells, (v) expression of dis-
tinct cell markers allowing their isolation [97-100]. CSCs
have been identified in many solid cancers, including
ovarian malignancies [101-109]. The identification of
ovarian CSCs is based on CD117 (c-kit), CD44, CD133
and ALDH markers as well as PKH67/PKH26 dyes
[99,102,110-112]. According to Silva et al., dual positivity
of CD133 and ALDH defines an effective cell population
of ovarian CSCs [111]. In limited dilution assays, a small
number of these cells are sufficient to initiate tumors.
Furthermore, they exhibit an increased angiogenic ability
compared to regular OCCs. In the clinical setting, the
presence of CSCs in ovarian tumors portends poor
survival outcomes, leading to increased tumor burden
and chemoresistance [113,114]. Their persistence within
a residual niche may therefore contribute to disease
recurrences.
We have recently reviewed the role of the microenvir-
onment in ovarian CSCs maintenance [115]. Among the
diverse stromal actors, cancer-associated MSCs are de-
terminant for the regulation of CSCs self-renewal via
increased expression of BMP-2 [81]. MacLean et al. re-
ported a 4- to 8-fold increase in the percentage of ovar-
ian CSCs in the presence of cancer-associated MSCs.
Interestingly, tumor stemness was only partially blocked
by the BMP inhibitor Noggin, suggesting the existence
of other redundant pathways. MSCs-derived IL-6 andIL-8, whose production is stimulated by LPA, participate
in CSCs promotion: IL-6 contributes to self-renewal of
CSCs and IL-8 to CSCs proliferation through its binding
to CXCR1 receptor [72,102,103,116,117].
Altogether MSCs engraftment at primary tumor site
positively impacts cancer progression, due to the com-
bination of several mechanisms including two-sided
phenotypic modulation and promotion of OCCs prolif-
eration and angiogenesis. MSCs also contribute to build
a suitable environment that will participate in the regu-
lation of ovarian cancer metastasis.
Metastatic niche: the concept of targeted spread
The “seed and soil” theory revisited
Based on autopsies of patients with breast cancer,
Stephen Paget’s “seed and soil” theory illustrates the
striking fact that a given tumor type will preferentially
metastasize to specific organs [118]. This tumor tropism
is clearly observed for certain cancers such as breast and
prostate adenocarcinomas that commonly metastasize to
bone tissue, or ovarian malignancies that typically spread
into the peritoneal cavity. One century later, David Tarin
reached a similar conclusion in patients with peritoneal
carcinomatosis from diverse cancers including primary
ovarian tumors [119]. While patients with peritoneo-
venous shunts had millions of cancer cells poured in
their blood circulation, they did not display more distant
metastasis nor decreased survival compared to patients
without shunts. Moreover, half of them did not develop
any distant metastasis up to 27 months survival. Some-
how, ovarian cancer is thus “programmed” to spread into
selected organs and steer away from others. Besides the
intrinsic abilities of cancer cells, tumor environment as
well as resident stroma cells of distant sites participate in
this targeted metastatic process.
The pre-metastatic niche
Lyden’s group has defined the concept of pre-metastatic
niche as the early changes that occur in the future meta-
static site before engraftment of cancer cells [79,120].
The constitution of such a niche dictates the pattern
of metastatic spread. In brief, bone marrow-derived
hematopoietic progenitor cells (HPCs) migrate to distant
sites in response to growth factors and inflammatory cy-
tokines secreted by the primary tumor. Kaplan et al. de-
scribe the existence of a complex loop where HPCs
VEGFR1+ form cellular clusters in tumor-specific pre-
metastatic sites before the arrival of cancer cells. Resi-
dent fibroblasts, possibly derived from MSCs and activated
by tumor-specific growth factors, secrete fibronectin, an
adhesion protein inducing VLA-4 (integrin α4β1) medi-
ated recruitment of HPCs [29]. α4β1 signaling induces
modifications of the local ECM mediated by MMP-9.
The microenvironment alteration enhances recruitment
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contexture through a cytokine network including TNFα,
MMP-9, TGFβ, and SDF1 [121]. SDF1 finally acts as a
chemo-attractant for both hematopoietic progenitor cells
(HPCs CXCR4+) and metastatic tumor cells (MTCs). In
the hypoxia context, lysyl oxidase secreted by hypoxic
tumor cells accumulates at pre-metastatic sites, resulting
in CD11b +myeloid cell recruitment and increased pro-
duction of MMP-2 [122]. MMP-2 favors tumor cells at-
tachment through the changes they mediate in ECM
[123]. MTCs subsequently engraft the permissive niche
and contribute to the constitution of micro-metastases.
However, the stromal role during the metastatic process
goes beyond the constitution of the pre-metastatic niche.
Primary tumor stroma may also participate in selecting
clones primed for metastasis in specific organs. In a triple
negative breast cancer model, Zhang et al. have demon-
strated that a tumor stroma rich in CAFs selects for can-
cer clones that fit to thrive on the CAF-derived cytokines
SDF1 and IGF1 and sheds the carcinoma population to-
ward a preponderance of such clones [124]. These clones
display a constitutively high level of Src activity and bone
metastatic ability contrary to most triple negative cancers
that prominently metastasize to visceral organs. CAFs pro-
vide a cytokine contexture (SDF1 and IGF1) similar to
bone marrow microenvironment and select metastatic
seeds compatible with the target organ.
Altogether, data in the literature support the concept
that the stroma actively participates in tumor promotion
and to the constitution of a permissive niche for meta-
static cells. It is thus a strong determinant of metastatic
tropism. While different tumor types have their own
physiopathology governing preferential sites for metastasis,
ovarian cancer spread at an advanced stage (above IIIC) is
limited to the peritoneum and distant blood-borne metas-
tases are quite rare [125,126]. The recurrences are also
often located within the abdominal cavity proposing the
role of a residual niche within the peritoneum.
Initial dissemination within peritoneal cavity
Initial dissemination of OCCs from primary tumor is
based on changes in expression of cellular adhesive pro-
teins (Figure 4). Intercellular adhesion in ovarian tumors
is mediated by N- and E-cadherin, and cell-matrix ad-
hesion by integrins [127]. Disruption of both cell-cell
contact and cell-matrix interactions results in the
shedding of single cells or muticellular aggregates into
peritoneal cavity. These ascitic OCCs undergo epithelial-
to-mesenchymal-transition, resulting in a phenotype with
low levels of E-cadherin and higher invasiveness and mo-
tility compared to primary tumor cells [128]. They also
display CSCs characteristics when clustered in compact
spheres, leading to increased chemoresistance and tumori-
genesis [99]. They migrate to distant areas following theflow of peritoneal fluid hence the geographical localization
of lesions within the abdomen at diagnosis. Ascites fluid
comprises more than 200 proteins in its soluble fraction,
including LPA, SDF1, cytokines such as RANTES, IL-1,
IL-6, IL-8 and IL-10, growth factors (EGF, VEGF, HB-EGF,
TGFβ, TNFα and CSF1) and ECM proteins such as colla-
gens I and III [129-136]. It thus constitutes a suitable
environment for OCCs survival.
Cellular components including inflammatory and meso-
thelial cells are also prevalent in ascites. We have isolated
stromal cells from ascites of patients presenting with ovar-
ian cancer [137]. These tumor associated mesenchymal
cells (TAMCs) were closely associated with tumor cells
(photo) and shared some homology with bone marrow-
and adipose- derived MSCs (CD9, CD10, CD29, CD146,
CD166, HLA-1) [24]. They might therefore represent a
differentiated stromal subset of MSCs. Converging data
support that TAMCs actively contribute to metastatic
process through different mechanisms. We have shown
that intra-peritoneal co-injection of TAMCs and OCCs
conferred a proliferative advantage to OCCs in a murine
model with enhanced tumor growth and development of
neoplastic ascites [24]. Noteworthy, TAMCs were prefer-
entially localised close to cancer cells, typically in the per-
iphery of tumors. Moreover, the presence of TAMCs was
associated with increased tumor vascularization. Concor-
dantly, HIF-1α and VEGF-A were overexpressed in tu-
mors and ascites, respectively, derived from the group that
received co-injection. Castells et al. failed to demonstrate
any proliferative effect of TAMCs on ECs [138]. Neverthe-
less they have shown the existence of a crosstalk between
TAMCs and macrophages yielding increased production
of pro-angiogenic cytokines, including IL-6, IL-8 and
VEGF.
TAMCs also display a protective role by inducing
chemoresistance and immunomodulation [23,137,139].
TAMCs inhibit both proliferation and cytokine produc-
tion in human CD4 and CD8 T-cells, allowing cancer
cells to evade immune surveillance. Therefore, the pro-
tection TAMCs provide prompts us to consider them as
a niche where tumor cells are sheltered against therapy.
Cancer dissemination in ovarian malignancies may
be sequential, from the primary tumor to abdominal
“milieu” and then to the peritoneum. Indeed, ascitic
OCCs might be the primary source of intraperitoneal
metastatic lesions. Their attachment to the peritoneum
constitutes the first step toward peritoneal infiltration.
Peritoneal carcinomatosis
Peritoneal involvement
Clinical presentation at baseline in patients with ad-
vanced stages includes ascites, peritoneal carcinomatosis
and omental involvement [140] (Figure 4). The peritoneum
is a complex organ constituting the microenvironment of
Figure 4 Early steps in peritoneal infiltration. Tumor-associated Mesenchymal Cells (TAMCs) constitute a protective niche for ascitic Ovarian
Cancer Cells (OCCs) through their inhibition of anti-cancer T cells. They also participate in angiogenesis at metastatic sites by inducing macrophages
production of pro-angiogenic cytokines including IL-6, IL-8 and VEGF. Ascitic OCCs may be the primary source of peritoneal metastases. The initiation
of peritoneal invasion relies on the ability of OCCs to attach to and to clear the mesothelial cells that constitute the peritoneum. This mesothelial
clearance involves integrin- and talin-dependent activation of myosin and allows OCCs to get access to the basement membrane. Bone marrow-derived
Mesenchymal Stem Cells (MSCs) are recruited at metastatic sites and favor the infiltration process with the release of secreted factors such as IL-6 and
MMP-2. The metalloprotease MMP-2 is also up regulated in OCCs upon binding to mesothelium and leads to improved attachment of tumor cells by
modifying the extracellular matrix.
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posed of a continuous mesothelial cell layer covering all
abdominal organs except ovaries. The peritoneum lies
on a basement membrane covering stromal tissue. This
stroma contains a collagen-based matrix (collagen types
I and III), blood and lymphatic vessels, nerve fibers and
fibroblastic-like cells (Figure 6). The peritoneum is con-
sidered as a tertiary lymphoid organ that allows fast
mobilization and recruitment of the inflammatory ma-
chinery to overcome abdominal injury or infection.
Hence many inflammatory cytokines are up regulated in
ovarian cancer ascites. Mesothelial cells also contribute
to peritoneal fluid dialysis, abdominal healing and forma-
tion of adherences [141,142]. Therefore, the peritoneum
constitutes a functional and anatomical barrier againstintra-abdominal aggression and is considered as the first
line of defense against cancer spread [143,144].
However the metastatic process manages to disrupt
the organisation of the mesothelial layer: during the
formation of carcinomatosis nodules, mesothelial cells
aggregate around the neoplastic lesion [145]. The mech-
anism used by OCCs to clear mesothelial cells and get
access to the basement membrane is complex and yet
poorly understood. Tumoral soluble factors may prime
mesothelial tissue for cancer spread. Indeed, mesothe-
lium in ovarian carcinomatosis displays morphological
changes and forms a discontinuous layer of hemispheric
cells [146]. This phenotypic alteration is associated with
modifications in transcriptomic profile, including modu-
lation of genes involved in inflammation, catalytic activity,
Figure 5 Macroscopic aspects of peritoneal carcinomatosis. (A) Isolated lesions. (B) Confluent lesions. (C) Typical “taches de bougie” lesions.
(D) Miliary lesions.
Figure 6 Pathological aspects of normal peritoneum and peritoneal metastasis.
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of surgical specimens has suggested that mesothelial
cells may nurture peritoneal metastases through the
production of growth factors such as VEGF and fibro-
blast growth factor 2 (FGF-2) [148]. The initiation of
peritoneal invasion also relies on the ability of OCCs to
attach to mesothelial cells through activation of CD44
and beta-1 integrin [149,150]. In their in vitro model,
Iwanicki et al. have shown that ovarian cancer spher-
oids use integrin- and talin-dependent activation of
myosin and traction force to promote displacement of
mesothelial cells [151]. This mesothelial clearance per-
mits OCCs to get access to the basement membrane
and to stromal cells that will then support their survival
and growth. MSCs play an important role along this
process, as supported by our 3D model of early peri-
toneal infiltration based on amniochorionic membrane
[33]. In serum free condition, OCCs became adherent
to the membrane within the first 24 hours following in-
cubation and started to infiltrate the stroma 48 hours
after adhesion. Infiltration was significantly deeper in
areas settled with MSCs, due to increased release of IL-6.
Therefore, MSCs generate a cytokine contexture suitable
for metastasis establishment. Metalloproteases such as
MMP-2 contribute through a feed-forward loop to cancer
cells peritoneal adhesion and invasion. MMP-2 expression
is up regulated in OCCs upon binding to mesothelium,
through direct cell-cell interaction involving mesothelial
cells [123]. MMP-2 is also produced by bone marrow-
derived MSCs recruited to the tumor site in response to
OCCs secretion of LL-37 [21]. MMP-2 over-expression
leads to increased degradation of ECM proteins such as
vibronectin and fibronectin. OCCs adhere more efficiently
to cleaved fragments, resulting in improved attachment.
Noteworthy, vibronectin and fibronectin production is
increased during the metastatic process. Resident fibro-
blasts, potentially deriving from resident MSCs, are
primed by tumor specific growth factors and and consti-
tute the main source of ECM proteins [29].
Omental infiltration
The omentum is a large fold of visceral peritoneum con-
taining fatty tissue. In a 3D culture model of omental
infiltration, Kenny et al. have demonstrated that OCCs
preferentially adhere to and invade through collagen I
and IV rather than fibronectin, vitronectin and laminin
[143]. Furthermore, resident cells differently impact
the metastatic process. While mesothelial cells inhibit
both adhesion and invasion, omental fibroblasts promote
OCCs attachment and infiltration. Similarly to peri-
toneal infiltration, MMP-2 over-expression observed
upon the interaction between OCCs and omental fibro-
blasts may promote tumoral infiltration [123]. Omental
MSCs (O-ASCs) also participate in the invasion process[152]. In a model of endometrial carcinoma, O-ASCs stim-
ulated cancer cells proliferation and promoted in vivo
tumor growth and vascularization [152]. Compared to the
control group, the tumors associated with O-ASCs con-
tained a more mature and extensive fibrovascular network.
These findings can be extrapolated to the omental invasion
occurring in ovarian cancer (Figure 7).
MSCs and chemoresistance
Microenvironement mediates resistance to therapy
The mainstay of treatment for ovarian cancer involves
complete cyto-reductive surgery associated with plati-
nium and taxane-based chemotherapy [153]. However,
most patients achieving complete initial clinical remis-
sion will develop recurrences and resistance to first
line drugs [154-156]. Acquired chemoresistance involves
many mechanisms: (i) alteration of the lipid membrane
modifying drug penetrance; (ii) increased capacity in
DNA repair; (iii) modification of drug targets; (iv) drug
inactivation mediated by metallothionein- or glutathione-
dependent mechanisms; (v) loss of drug surface trans-
porter; (vi) drug clearance by efflux pump [137]. Such
resistance mechanisms consist in long-term processes
and usually arise after multiple courses of chemotherapy
[155,157]. They develop over time as a result of sequen-
tial genetic changes that ultimately culminate in some
complex therapy-resistant phenotypes.
However, acquired chemoresistance cannot explain
most of treatment failures in ovarian cancer. The major-
ity of recurrences will occur within the first two years
following completion of initial treatment. Primary resist-
ance to treatment only concerns a low subgroup of early
relapses (up to 6 months after initial treatment). Other
diseases are considered platinium-sensitive. Therefore,
in addition to casual mechanisms of acquired resistance,
the microenvironment might mediate a kind of de novo
drug resistance leading to the persistence of a hidden
residual disease responsible for a subsequent relapse.
First evidences were provided in 1990 by Teicher et al.
[158]. In a murine breast cancer model, long-term ex-
posure to treatment was responsible for chemoresistance
in tumor-bearing animals. Nevertheless, in spite of high
levels of in vivo resistance, no significant resistance was
observed when cancer cells were exposed to the same
drugs in vitro. These findings set up the stage for the
paradigm that drug resistance can develop through
mechanisms that are expressed only in vivo and may
involve the crosstalk between cancer and stromal cells.
Somehow the microenvironment could protect the
tumor cells from the effects of anticancer agents.
The cross talk between cancer and stromal cells is
responsible for changes in ECM and cytokines release.
Reciprocal integrin- and soluble factor-mediated inter-
action induces in cancer cells a transient drug resistant
Figure 7 Pathological aspects of normal omentum and omental metastasis.
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Over time, genetic instability inherent to tumor cells
combined with selective pressure of therapy will result
in successive and random genetic changes. Such modifi-
cations will cause the gradual development of more com-
plex and permanent acquired-resistance phenotypes, and
relapses may originate from these persistent cancer cells.
MSCs actively contribute to environment-mediated resistance
The microenvironment provides a transient protection
while OCCs are acquiring genetic changes. Oncologic
trogocytosis perfectly illustrates this mechanism: through
a membrane uptake, cancer cells can get new functional-
ities. We have observed such hetero-cellular interaction
between TAMCs and OCCs [137]. Trogocytosis allowed
OCCs to acquire functional multidrug resistance proteins
from TAMCs membrane, including P-gp and LRP. Such
mechanisms have been described in other tumors as
well [159,160].
MSCs are responsible for phenotypic modulation to-
ward more aggressive cancer cell clones. We have pro-
posed a transcriptomic approach in OCCs co-cultured
with MSCs [32]. The analysis revealed that 3 biological-
function gene clusters were enriched in OCCs upon
contact with MSCs, comprising metastatic, proliferative
and chemoresistance abilities. Concordantly, OCCs co-
cultured with MSCs displayed chemoresistance to taxol
and carboplatin. MSCs-derived secreted factors are alsoable to confer chemoresistance to platinium in OCCs, as
supported by the decrease of carboplatin-induced apop-
tosis in the presence of MSCs condition medium [139].
This apoptosis blockade is mediated by the activation
of the phosphatidylinositol 3-kinase/Akt signaling path-
way and the phosphorylation of its downstream regulator
X-linked inhibitor of apoptosis (XIAP).
Microenvironment protection may have contributed to
the disappointing results of hyperthermic intraoperative
chemotherapy (HIPEC) for stage IIIC ovarian cancers
[161,162]. HIPEC procedure involves a complete resec-
tion of abdominal disease followed by intra peritoneal
infusion of Oxaliplatin at 42-44°C. We have demon-
strated that hyperthermia did not challenge survival of
bone marrow-derived and cancer-associated MSCs
[25]. Furthermore, in the context of hyperthermia, MSCs
induced a thermo tolerance in OCCs through SDF1 secre-
tion. The inhibition of SDF1/CXCR4 interaction restored
cytotoxicity of hyperthermia.
Circulating MSCs, observed in advanced-stage ovarian
malignancies, are also involved in chemoresistance. They
are activated by platinium-derived drugs and in turn
secrete fatty acids (PIFAs) that, in discrete quantities,
confer OCCs resistance to several types of anti-cancer
agents [34]. PIFAs induce acute and reversible preven-
tion of apoptosis in cancer cells through an indirect and
yet undetermined effect that can be prevented by con-
comitant infusion of cyclooxygenase-1 inhibitor.
Figure 8 Overview of the role of Mesenchymal Stem Cells along tumorigenesis.
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cancer through many mechanisms. Anti-tumor therapy
should thus be associated to additional therapies targeting
tumor-stroma interactions. Such therapeutic combination
would prevent from temporary microenvironment-
mediated drug resistance and might suppress any minimal
residual disease. In the era of personalized medicine, it rep-
resents one of the biggest challenges for further therapeutic
approaches in ovarian cancer.
Conclusion
Tumor stroma and microenvironment represent a corner-
stone in the regulation of OCCs behavior (Figure 8). MSCs
contribute to each step of cancer spread, from proliferation
to chemoresistance, from infiltration to metastasis. The
crosstalk between MSCs and OCCs is based on complex
mechanisms, involving cell-cell interaction and secreted
factors. Beyond casual phenotypic changes they generate in
tumor cells, MSCs provide a smart environment-mediated
resistance protecting residual disease from treatment while
acquired mechanisms are developing. OCCs and MSCs
clearly constitute a deadly cocktail, offering the disease a
multi-potent partner. Therefore, to enhance suppression of
any residual disease, future therapeutic approaches should
thus combine anti-tumor therapy to new molecules target-
ing tumor-stroma interactions.
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